Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
Author: Global Cancer Consortium
In response to some recent successes by several companies operating in the cervical cancer space, we are issuing a two-part special report exploring pre-cervical cancer and CIN.
OneMedRadio interviewed, Andrew Senyei, an MD with an interest in individualized DNA sequencing and gene therapy for heart disease.
In Part III of our interview with Dr. Qin Shi of Edgetech Law we visit the concept of human genome sequencing as a mainstream commodity.
Peter Winter, consultant to the biotechnology industry brings us financings and business developments in the global diagnostics business in his column “This Week In Diagnostics“. Peter has over 30 years experience as a scientist, science journalist, and publisher.
In Part II of our special interview series, Dr. Qin Shi of Edgetech Law discusses the emerging areas of significant unmet need in life science, and what investment opportunities may arise.
Biovest International, Inc. (OTCQB: BVTI) announced that Biovest is seeking marketing approval in Canada for BiovaxID®, its personalized cancer vaccine for the treatment of follicular non-Hodgkin’s lymphoma.
OneMedRadio recently conducted an interview with Dr. Clifford A. Reid, the company’s President and Chief Executive Officer.